Characterization of a designed vascular endothelial growth factor receptor antagonist helical peptide with antiangiogenic activity in vivo(985 views) Basile A, Del Gatto A, Diana D, Di Stasi R, Falco A, Festa M, Rosati A, Barbieri A, Franco R, Arra C, Pedone C, Fattorusso R, Turco MC, D'Andrea LD
J Med Chem (ISSN: 1520-4804, 0022-2623, 0022-2623print), 2011 Mar 10; 54(5): 1391-1400.
Keywords: Acetyllysylglutaminylmethionyltyrosylleucylglutamylleucylglycyltyrosylalanylthreonylisoleucyllysyltryptophanylleucine Amide, Acetyllysylleucylthreonyltryptophanylmethionylglutamylleucyltyrosylglutaminylleucylalanyltyrosyllysylglycylisoleucine Amide, Angiogenesis Inhibitor, Caspase 3, Unclassified Drug, Vasculotropin, Vasculotropin Receptor, Vasculotropin Receptor Antagonist, Amino Terminal Sequence, Animal Experiment, Animal Model, Animal Tissue, Antiangiogenic Activity, Article, Cancer Inhibition, Cell Activation, Cell Proliferation, Cell Survival, Controlled Study, Drug Conformation, Drug Efficacy, Drug Mechanism, Drug Receptor Binding, Drug Stability, Drug Structure, Endothelium Cell, Enzyme Activity, Female, Human, Human Cell, In Vivo Study, Inhibition Kinetics, Melanoma, Mouse, Nonhuman, Peptide Synthesis, Tumor Xenograft, Cultured, Circular Dichroism, Endothelial Cells, Magnetic Resonance Spectroscopy, Nude, Molecular, Neoplasm Transplantation, Neovascularization, Pathologic, Protein Structure, Secondary, Vascular Endothelial Growth Factor, Signal Transduction, Heterologous, Umbilical Veins, Water,
Affiliations: *** IBB - CNR ***
Dipartimento di Scienze Farmaceutiche, Universita di Salerno and BioUniverSA SRL, Salerno, Italy.
Istituto di Biostrutture e Bioimmagini, CNR, Via Mezzocannone 16, 80134 Napoli, Italy
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy
Dipartimento Delle Scienze Biologiche, Università di Napoli Federico II, Napoli, Italy
References: Not available.
Characterization of a designed vascular endothelial growth factor receptor antagonist helical peptide with antiangiogenic activity in vivo
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(639 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote